Clinical Trials for Asthma
222 asthma trials indexed, 104 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Asthma
Asthma is a chronic lung condition that causes inflammation and narrowing of the airways. This inflammation makes it harder for air to move in and out of the lungs. The underlying biology involves the immune system reacting to certain triggers, which leads to swelling and increased mucus production in the airways. Asthma is diagnosed through a combination of patient history, physical examination, and lung function tests. Spirometry is a common test used to measure how much air a person can exhale and how quickly, helping doctors confirm the diagnosis.
Common symptoms of asthma include wheezing, coughing, shortness of breath, and chest tightness. These symptoms can vary in severity and often worsen at night or during exercise. Asthma can start at any age but often begins in childhood. It affects people of all ages and backgrounds, but children and young adults are among the most commonly affected groups. Risk factors include family history of asthma or allergies, exposure to tobacco smoke, air pollution, and respiratory infections during early childhood.
Asthma is a significant medical and social concern because it affects millions worldwide and can lead to serious complications if not well managed. According to the World Health Organization, over 260 million people suffer from asthma globally, and it causes around 461,000 deaths annually. In the United States alone, asthma leads to nearly 2 million emergency room visits each year. This condition also has a large economic impact, costing the U.S. healthcare system billions of dollars annually in hospital stays, medications, and lost workdays.
The Asthma Treatment Landscape
The first line of treatment for asthma usually involves inhaled corticosteroids (ICS) to reduce airway inflammation. These drugs are often combined with short-acting beta-agonists (SABA) that provide quick relief from symptoms by relaxing airway muscles. Treatment is typically tiered based on severity, starting with as-needed SABA for mild cases and adding low-dose ICS for persistent symptoms. If asthma remains uncontrolled, doctors may increase the dose or add other medications to the regimen.
For patients who do not respond well to first-line therapies, second- and third-line options include long-acting beta-agonists (LABA), leukotriene receptor antagonists (LTRA), and biologic therapies. LABAs help keep airways open for longer periods and are often used in combination with ICS. LTRAs block chemicals that cause airway inflammation and are an alternative for some patients. Biologic drugs, such as omalizumab, target specific immune pathways and are reserved for severe asthma cases that do not respond to standard treatments.
Despite these options, there are still gaps in asthma treatment. Some patients experience poor control due to resistance to medications or side effects like oral thrush from inhaled steroids. Others may have severe asthma subtypes that do not respond well to current drugs. Research is focusing on developing new therapies that target different parts of the immune system and improving personalized treatment approaches. Closing these gaps is important for reducing hospitalizations and improving quality of life for people with asthma.
Why Clinical Trials Matter for Asthma
Clinical trials offer patients the chance to access new treatments before they become widely available. Participation also allows for closer monitoring of health and symptoms by medical professionals. Contributing to clinical trials helps advance scientific understanding of asthma and improves future care options. Currently, there are 222 asthma clinical trials indexed on ClinicalTrials.gov, with 104 actively recruiting participants. This shows ongoing efforts to find better treatments and management strategies.
Taking part in a clinical trial comes with risks. New treatments may not be effective or could cause unexpected side effects. Some trials include placebo groups, meaning some participants do not receive the active treatment. Additional clinic visits and tests may be required, which can be time-consuming. It is important for participants to understand these factors and discuss them with their healthcare providers before enrolling.
Clinical trials for asthma are sponsored by a variety of organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors design and fund studies to test new drugs, devices, or treatment strategies. ClinicalTrials.gov serves as a central registry where information about ongoing and completed trials is publicly available. This transparency helps patients, caregivers, and healthcare providers find relevant studies and stay informed about research progress in asthma care.
What to Look for in a Asthma Clinical Trial
Clinical trials are divided into four main phases. Phase 1 tests a new treatment in a small group to check safety and dosage. Phase 2 involves more participants to see if the treatment works and to further evaluate safety. Phase 3 compares the new treatment to the current standard in large groups. Phase 4 happens after approval, monitoring long-term effects. For asthma trials, the distribution is as follows: 56 trials have no phase listed, 34 are in Phase 2, 24 in Phase 3, and 14 in Phase 4. Most trials are in Phase 2, focusing on effectiveness and safety.
Inclusion criteria for asthma trials often focus on age, with many studies including participants from children to older adults. Patients usually must have a confirmed asthma diagnosis and may need to show certain biomarkers or lung function test results. Some trials require participants to have used specific asthma treatments before enrolling. The stage or severity of asthma can also be a factor, as some trials look for mild cases while others target severe or uncontrolled asthma. The duration of the disease might be considered to understand how long the participant has been affected.
Exclusion criteria are important to keep participants safe and ensure clear results. People with other serious health conditions, such as heart disease or uncontrolled diabetes, are often excluded. This is to avoid complications or interactions with the study drug. Some trials exclude patients taking certain medications that might interfere with the treatment being tested. Safety thresholds, like lung function limits or recent asthma attacks, can also exclude participants to reduce risks during the trial.
Practical considerations matter for patients thinking about joining a trial. The length of the study can vary from a few weeks to several months or longer. Visit schedules may require frequent trips to the clinic or hospital. Travel distance and costs should be discussed upfront. Patients should ask the research team specific questions like: How many visits will I need? What tests or procedures will be done? Are there any side effects I should watch for? What support is available if I have problems during the trial?
Primary Sources and Further Reading
For those interested in learning more about asthma and clinical trials, it is helpful to consult trusted sources. These websites provide detailed information on asthma management, research updates, and how clinical trials work. They can guide patients and caregivers in making informed decisions about trial participation.
- MedlinePlus: Asthma
- National Heart, Lung, and Blood Institute: Asthma
- ClinicalTrials.gov: Asthma Trials
- Centers for Disease Control and Prevention: Asthma
Latest Research and Emerging Treatments for Asthma (2026)
Asthma research in 2026 continues to explore new drugs for asthma that may improve symptom control and reduce attacks. One such drug is benralizumab, a biologic treatment being studied in children aged 6 to under 18 with severe eosinophilic asthma (NCT05692180). Benralizumab works by targeting specific immune cells called eosinophils, which are involved in airway inflammation. Early data suggests that reducing these cells can help lower the frequency of asthma exacerbations. For young patients, this could mean fewer hospital visits and better daily breathing.
Another promising asthma treatment is dupilumab, tested in children aged 2 to under 6 years with uncontrolled asthma or severe wheezing (NCT06191315). Dupilumab blocks certain proteins that cause inflammation in the lungs, helping to calm the immune system. If successful, this new asthma treatment 2026 could offer families an option to manage symptoms more effectively at a young age. Additionally, tezepelumab is being studied in children and adults to see if it can reduce asthma attacks and allow patients to lower their use of other medications (NCT06023589, NCT06473779). This drug targets a molecule involved in multiple inflammatory pathways, which might help control asthma in patients not well managed by current therapies.
For adolescents and adults with severe uncontrolled asthma, GB-0895 is being tested as an add-on therapy (NCT07276724). This treatment aims to improve asthma control when standard medications are not enough. These ongoing Phase 3 trials reflect the continued effort to find safer and more effective options. For patients and caregivers, new drugs for asthma could mean better quality of life, fewer side effects, and less worry about sudden attacks. Keeping an eye on these studies may provide hope for improved asthma management in the near future.
Frequently asked questions about Asthma trials
How do I find Asthma clinical trials?
The authoritative source for Asthma clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 222 asthma studies are currently indexed. You can search by entering "asthma" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new asthma trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Asthma trials in?
Across the 222 asthma trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Asthma clinical trials are currently recruiting?
As of the latest scan, 104 asthma trials have a "Recruiting" status on ClinicalTrials.gov, out of 222 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting asthma trial matches their tracked condition.
Stay informed about asthma research
Get a weekly briefing with the trials that matter most.